Absorption, Distribution, Excretion, and Pharmacokinetics of -Pyronaridine Tetraphosphate in Male and Female Sprague-Dawley RatsReport as inadecuate

Absorption, Distribution, Excretion, and Pharmacokinetics of -Pyronaridine Tetraphosphate in Male and Female Sprague-Dawley Rats - Download this document for free, or read online. Document in PDF available to download.

Journal of Biomedicine and BiotechnologyVolume 2010 2010, Article ID 590707, 9 pages

Research ArticleRadiation Research Division for Biotechnology, Korea Atomic Energy Research Institute, 1266 Shinjeong-dong, Jeongeup, Jeonbuk 580-185, South Korea

Received 15 July 2009; Revised 28 October 2009; Accepted 18 January 2010

Academic Editor: Ayman El-Kadi

Copyright © 2010 Sang Hyun Park and Kannampalli Pradeep. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The main objective of this investigation was to determine the absorption, distribution, excretion, and pharmacokinetics of the antimalarial drug pyronaridine tetraphosphate PNDP in Sprague-Dawley rats. Following oral administration of a single dose 10 mg-Kg of -PNDP, it was observed that the drug was readily absorbed from the small intestine within 1 hour following oral administration and was widely distributed in most of the tissues investigated as determined from the observed radioactivity in the tissues. The peak value of the drug in the blood was reached at around 8 hours postadministration, and radioactivity was detected in most of the tissues from 4 hours onwards. -PNDP showed a poor permeability across the blood-brain barrier, and the absorption, distribution, and excretion of -PNDP were found to be gender-independent as both male and female rats showed a similar pattern of radioactivity. Excretion of the drug was predominantly through the urine with a peak excretion post 24 hours of administration. A small amount of the drug was also excreted in the feces and also in the breath. It was found that the , AUC 0-inf, and values were similar to those observed in the Phase II clinical trials of pyronaridine-artesunate Pyramax conducted in Uganda.

Author: Sang Hyun Park and Kannampalli Pradeep

Source: https://www.hindawi.com/


Related documents